Home > Signaling Pathways>Immunology/Inflammation>Glucocorticoid Receptor>Desisobutyryl-ciclesonide (CIC-AP; Ciclesonide active principle)
Desisobutyryl-ciclesonide (CIC-AP; Ciclesonide active principle)

This product is for research use only, not for human use. We do not sell to patients.

Desisobutyryl-ciclesonide (CIC-AP; Ciclesonide active principle)
For small sizes, please check our retail website as below: www.invivochem.com
Size Price Stock
100mg$750Check With Us
250mg$1350Check With Us
500mg$2025Check With Us
email: [email protected]        [email protected]

Cat #: V32506 CAS #: 161115-59-9 Purity ≥ 99%

Description: Desisobutyryl-ciclesonide (CIC-AP; Ciclesonide active principle) is a major active metabolite of Ciclesonide.

References: Silvestri M, et al. Ciclesonide modulates in vitro allergen-driven activation of blood mononuclear cells and allergen-specific T-cell blasts. Immunol Lett. 2012 Jan 30;141(2):190-6.

Top Publications Citing Invivochem Products
Product Catalog 2022
Bulletin Board
Guide to Product Handling
Publications Citing InvivoChem Products
Product Promise
Promise
Molecular Weight (MW)470.60
Molecular FormulaC28H38O6
CAS No.161115-59-9
SMILES CodeO=C1C=C[C@]2(C)[C@@]3([H])[C@@H](O)C[C@]4(C)[C@]5(C(CO)=O)O[C@H](C6CCCCC6)O[C@]5([H])C[C@@]4([H])[C@]3([H])CCC2=C1
Synonymsdes-Ciclesonide; desCiclesonide; des Ciclesonide; Cic2; Cic 2; Cic-2; Desisobutyrylciclesonide; Des-CIC; DesCIC; Des CIC;
ProtocolIn VitroCiclesonide, an inhaled corticosteroid with almost no affinity for the glucocorticoid receptor, is highly effective in downregulating in vitro pro-inflammatory activities of airway parenchymal cells when converted into the active metabolite Desisobutyryl-ciclesonide. Peripheral blood mononuclear cell proliferation to C. albicans is dose-dependently inhibited by 0.3-3.0 μM Ciclesonide and Desisobutyryl-ciclesonide but inhibition by Desisobutyryl-ciclesonide is higher. A significant proliferation to PhlP5 is observed only in cultures from atopic subjects: an effective downregulation is already detected at 0.03 μM Ciclesonide and 0.003 μM Desisobutyryl-ciclesonide (complete inhibition at 3 μM Ciclesonide and 0.03 μM Desisobutyryl-ciclesonide). 3 μM Ciclesonide and Desisobutyryl-ciclesonide reduce the PhlP5-specific T-cell blast proliferation and interleukin 4-producing cell proportion. In PBMCs cultures from atopic patients, both Ciclesonide (CIC) and Desisobutyryl-ciclesonide (des-CIC) induce a dose-dependent downregulation of PhlP5-induced proliferation. The effect is already significantat 0.03 μM Ciclesonide and at 0.003 μM Desisobutyryl-ciclesonide (p<0.001, each comparison),with an early complete inhibition observed at 3μM Ciclesonide and at 0.03 μM Desisobutyryl-ciclesonide. The inhibitory activity toward PhlP5-induced PBMC proliferation is higher for Desisobutyryl-ciclesonide than for Ciclesonide at 0.003 μM (p<0.05), 0.03 μM (p<0.001) and 0.3 μM (p<0.05).
These protocols are for reference only. InvivoChem does not independently validate these methods.
Preparing Stock Solutions
Solvent volume to be added Mass (the weight of a compound)
Mother liquor concentration 1mg5mg10mg20mg
1mM2.1249 mL10.6247 mL21.2495 mL42.4989 mL
5mM0.4250 mL2.1249 mL4.2499 mL8.4998 mL
10mM0.2125 mL1.0625 mL2.1249 mL4.2499 mL
20mM0.1062 mL0.5312 mL1.0625 mL2.1249 mL
The molarity calculator equation
Mass(g) = Concentration(mol/L) × Volume(L) × Molecular Weight(g/mol)
Mass
 
=
Concentration
 
×
Volume
 
×
Molecular Weight*
The dilution calculator equation
Concentration(start) × Volume(start) = Concentration(final) × Volume(final)

This equation is commonly abbreviated as: C1 V1 = C2 V2

Concentration(start)
C1
 
×
 
Volume(start)
V1
 
=
 
Concentration(final)
C2
 
×
 
Volume(final)
V2
Step One: Enter information below
Dosage mg/kg Average weight of animals g Dosing volume per animal µL Number of animals
Step Two: Enter the in vivo formulation
%DMSO + % + %Tween 80 + %ddH2O
Calculation Results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in µL DMSO(Master liquid concentration mg/mL) ,Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation: Take µL DMSO master liquid, next add µL PEG300, mix and clarify, next add µL Tween 80,mix and clarify, next add µL ddH2O,mix and clarify.
Note:
  • (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
  • (2) Be sure to add the solvent(s) in order.